Lam Research heads into Tuesday's Q4 print having shed another 4.6% on Thursday, closing at $305.21 — a stock now trading 18% below where it was just a month ago and more than 29% off its late-June peak near $433.
The price action remains a sector story, not an idiosyncratic one. Thursday's drop tracked closely with peers: AMAT fell 4.7%, MKSI dropped 4.7%, UCTT declined 7.8%, and ICHR shed nearly 8%. ENTG is now down almost 7% on the week, the weakest in the group. The semiconductor equipment complex is undergoing a broad de-rating, and has simply moved with it. What makes the setup striking is that short sellers are not driving the decline. Short interest has fallen roughly 18% over the past month to just 2.1% of the free float — a low reading with no meaningful upward pressure. Borrowing costs have collapsed from above 1% in late June to 0.27%, and availability is essentially unlimited, with nearly one billion shares available to borrow. The selling is coming from longs exiting, not shorts pressing in.
The analyst community, by contrast, has turned decisively constructive. Every recent analyst action has been a target raise, not a cut. Morgan Stanley lifted its target to $404 in early July. Stifel moved to $425. Mizuho, TD Cowen, and Needham all raised targets into the $390–$425 range. BofA set $480 and Cantor Fitzgerald went to $500. The consensus mean now sits at $372 — a 22% premium to the current price. Bulls point to LRCX's dominant position in etch and CVD equipment, its exposure to high-bandwidth memory demand, and a track record of double-digit earnings beats. Bears acknowledge the franchise quality but flag the cyclicality of WFE spending and the stock's reliance on memory chipmakers at a moment when the spending cycle's durability is in question. The gap between where the stock trades and where analysts think it belongs is unusually wide — and unusually uncomfortable heading into a print.
Options positioning reflects that discomfort. The put/call ratio has climbed to 1.20, running above its 20-day average of 1.14 and at a z-score of 1.3 — elevated but not extreme. Investors are paying more for downside protection, though the move is not yet at the fearful end of the range. The EPS momentum picture remains strong: ORTEX factor scores rank LRCX in the 95th percentile on 30-day EPS momentum and 90th on 90-day momentum, suggesting the fundamental earnings trajectory has not broken down even as the stock has. The last two prints produced muted immediate reactions — a fractional gain in April, a 4% rise in January — but five-day returns were negative both times, at -3.7% and -12% respectively.
Tuesday's print is less a test of whether Lam Research can beat the numbers and more a test of whether guidance is strong enough to close the widening gap between a deeply discounted stock and a still-constructive analyst consensus.
See the live data behind this article on ORTEX.
Open LRCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
